Products
Platform
Research
Market
Learn
Partner
Support
IPO

A

Akums Drugs & Pharmaceuticals Share Price

429.3
-8.05 (-1.84%)
AKUMS • 20 Jan, 2026 | 11:44 AM
Buywith MTF at 3.29x leverage
The current prices are delayed, login or Open Demat Account for live prices.

Akums Drugs & Pharmaceuticals Stock Performance

1W Return-3.28
1Y Return-31.48
Today's Low429.15
Prev. Close437.35
Mkt Cap (Cr.)6,883.63
1M Return0.49
3Y Return0.00
52-Week High636
Open439.00
PE Ratio50.21
6M Return-22.35
Today's High441
52-Week Low405
Face Value2

Akums Drugs & Pharmaceuticals Company background

Founded in: 2004
Managing director: SANDEEP JAIN
Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.Alkums Drugs Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as antiinfective, respiratory and diabetes. In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones dedicated a facility for cosmetics and dermatology at Haridwar, Uttarakhand. In 2010, it incorporated Akumentis Healthcare Limited to venture into branded formulations.In 2011, it innovated bilayered sustained release tablets for the first time. In 2012, acquired subsidiary, Pure and Cure Healthcare Private Limited to expand capacity and capabilities. In 2013, it acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities. It established RD Laboratory in Mumbai, Maharashtra to venture into regulated market in 2015. In 2021, the Company acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs. Further, it acquired Kotdwar Plant in Uttarakhand by Akums Healthcare Limited. In 2022, it acquired facility in Haridwar, Uttarakhand through the subsidiaries, Akums Healthcare Limited and in 2023, acquired Baddi facility in, Himachal Pradesh through Pure and Cure Healthcare Private LimitedFollowing a Scheme of Arrangement on October 17, 2023, Akums Lifesciences Limited got merged with its subsidiary, Pure and Cure Healthcare Private Limited (PCHL) with effect from April 1, 2022. As part of this acquisition, it acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an RD centre in Barwala, Haryana and commenced operations in the manufacture and sale of key starting materials, intermediates and APIs. The Company launched an IPO by issuing 27,368,151 equity shares of Rs 2 each by raising funds aggregating to Rs 1857 Crore comprising a fresh issue of 10,037,716 equity shares aggregating to Rs 680 Crore and offer for sale of 17,330,435 equity shares aggregating to Rs 1177 Crore in August, 2024.Akums Healthcare UK Ltd. was incorporated as a foreign wholly owned subsidiary of the Company on 18th March, 2025. The new stateoftheart facilities at Kotdwar and Haridwar, focusing on Penem anti infectives and general injectables, have enhanced the manufacturing capacity in FY 2025.

Akums Drugs & Pharmaceuticals Financial Highlights


For the full year FY2025–2026, revenue reached ₹4170.28 crore and profit touched at ₹343.78 crore. As of Dec '25, Akums Drugs & Pharmaceuticals’s market capitalisation stood at ₹6,883.63 crores. Shareholding as of Dec '25 shows promoters holding 75.3%, with FIIs at 1.1%, DIIs at 14.5%, and public at 6.4%.

Akums Drugs & Pharmaceuticals Share Price Today


As of 20 Jan 2026, Akums Drugs & Pharmaceuticals share price is ₹429.3. The stock opened at ₹439 and had closed at ₹437.4 the previous day. During today’s trading session, Akums Drugs & Pharmaceuticals share price moved between ₹429.15 and ₹441.00, with an average price for the day of ₹435.07. Over the last 52 weeks, the stock has recorded a low of ₹405.00 and a high of ₹636.00. In terms of performance, Akums Drugs & Pharmaceuticals share price has declined by 22.4% over the past six months and has declined by 29.11% over the last year.
Read More
View details of Market Depth

Akums Drugs & Pharmaceuticals Fundamental

Market Cap (in crs)

6,883.63

Face Value

2

Turnover (in lacs)

168.75

Key Metrics

Qtr Change %
32.44% Fall from 52W High
-7
Dividend yield 1yr %
0

Akums Drugs & Pharmaceuticals Key Financials

View more
Loading chart...
Akums Drugs & Pharmaceuticals Quarterly Revenue
Akums Drugs & Pharmaceuticals Yearly Revenue
Akums Drugs & Pharmaceuticals Quarterly Net Profit/Loss
Akums Drugs & Pharmaceuticals Yearly Net Profit/Loss

Akums Drugs & Pharmaceuticals Result Highlights

  • Akums Drugs & Pharmaceuticals Ltd reported a 0.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.3%.

  • Its expenses for the quarter were up by 3.0% QoQ and 2.7% YoY.

  • The net profit decreased 34.0% QoQ and decreased 35.9% YoY.

  • The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 2.66 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Akums Drugs & Pharmaceuticals Shareholding Pattern

Promoter
75.3%
Foreign Institutions
1.1%
Mutual Funds
11.2%
Domestic Institutions
14.5%
Public
6.4%

Akums Drugs & Pharmaceuticals Technical Analysis

Moving Averages Analysis
429.3
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
Day EMA5
442.30
Day EMA10
443.80
Day EMA12
443.80
Day EMA20
442.60
Day EMA26
441.70
Day EMA50
442.50
Day EMA100
456.10
Day EMA200
503.70
Delivery & Volume
Loading chart...

Day

45.40%

Week

53.80%

Month

25.80%

Delivery & Volume

440.05
Pivot
Resistance
First Resistance
443.10
Second Resistance
448.85
Third Resistance
451.90
Support
First Support
434.30
Second support
431.25
Third Support
425.50
Relative Strength Index
45.88
Money Flow Index
50.30
MACD
2.10
MACD Signal
3.33
Average True Range
10.35
Average Directional Index
31.48
Rate of Change (21)
3.98
Rate of Change (125)
-21.93
Compare

Akums Drugs & Pharmaceuticals Latest News

07 JAN 2026 | Wednesday
28 DEC 2025 | Sunday
27 DEC 2025 | Saturday

Please be aware that Akums Drugs & Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account